Skip to main content

Table 2 Comparison of KarMMa (bb2121) and LEGEND-2 (LCAR-B38M) clinical studies

From: Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma

  bb2121 / KarMMa [59] LCAR-B38M / LEGEND-2 (Xi’an site) [49, 50]
Alternative product name ide-cel cilta-cel
Trial # (study phase) NCT03361748 (phase II) NCT03090659 (phase I)
n of patients 128 (54 at RD of 450 × 106) 57
Expansion method aCD3 + aCD28 aCD3/CD28 + IL-2
Loading method Lentiviral Lentiviral
CAR-T structure Murine scFv Llama 2xVHH
Lymphodepletion CP/Flu CP
CAR-T cell dosage(s) 150–300 to 450 × 106 32.3 × 106 (3.3 to 126.2 × 106)
Patient characteristics   
 Age (range), y 61 (33–78) 54 (27–72)
 Median n PLT (range) 6 (3–16) 3 (1–9)
 High-risk featuresa 51% 37%
CRS 96.3%b 89.5%
 Gr. 1–2 90.7% 82.5%
 Gr. ≥ 3 5.6% 7.0%
 Median onset (range) 1d (1–10) 9d (1–19)
 Median duration (range) 7d (1–63) 9d (3–57)
 Tocilizumab use 67% 46%
Neurotoxicity 20.4%b 1.8%
ORR 82%b 88%
 MRD CR 28% 68%
 CR 11% 5%
 VGPR 26% 4%
 PR 17% 11%
Median PFS (95% CI) 12.1m (8.8–12.3)b 19.9m (9.6–31)
  1. aCD3 + aCD28 = anti-CD3 and anti-CD28 antibodies. aCD3/CD28 + IL-2 = anti-CD3 and anti-CD28-coated beads plus interleukin-2. cilta-cel = ciltacabtagene autoleucel. CP = cyclophosphamide. CP/Flu = cyclophosphamide plus fludarabine. CR = complete response. CRS = cytokine release syndrome. d = days. Gr. = grade. ide-cel = idecabtagene vicleucel. m = months. MRD = minimal residual disease. n = number. ORR = objective response rate. PFS = progression-free survival. PLT = prior lines of treatment. RD = recommended dose. scFv = single-chain variable fragment. (VG)PR = (very good) partial response. VHH = heavy-chain variable region. Trial # = study registration number in Clinicaltrials.gov (NCT#). y = years
  2. aHigh-risk defined as R-ISS stage 3 and/or high-risk genetics (del(17p), t(4;14), t(14;16))
  3. bData shown for the 450 × 106 dose cohort only